Skip to main
NVRO
NVRO logo

Nevro (NVRO) Stock Forecast & Price Target

Nevro (NVRO) Analyst Ratings

Based on 24 analyst ratings
Hold
Strong Buy 17%
Buy 21%
Hold 46%
Sell 13%
Strong Sell 4%

Bulls say

Nevro Corp has demonstrated strong revenue growth in the latter half of the year, supported by a comprehensive guidance that includes trials, replacements, competitive conversions, and new patients for 2024. The ongoing scaling of its Costa Rica manufacturing facility is expected to enhance gross margins over the long term, while improvements in operational efficiency are poised to further strengthen profitability. The company is actively investing in its R&D pipeline and diversifying its portfolio, which, along with strategic changes to its commercial team, positions Nevro favorably for continued growth and enhanced market penetration.

Bears say

Nevro Corp's outlook is negatively impacted by a sequential revenue decline, as Q4 revenue of $96.9 million represented a 7% year-over-year decrease, coupled with a 15.2% drop in U.S. trial procedures on an annual basis. The company has also revised its full-year 2024 revenue guidance downwards, projecting $400-405 million, reflecting a decline of 5-6% year-over-year. Furthermore, anticipated lower gross margins in Q4 2024, combined with decreased sales volumes, are expected to create ongoing margin pressures into 2025.

Nevro (NVRO) has been analyzed by 24 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 21% recommend Buy, 46% suggest Holding, 13% advise Selling, and 4% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nevro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nevro (NVRO) Forecast

Analysts have given Nevro (NVRO) a Hold based on their latest research and market trends.

According to 24 analysts, Nevro (NVRO) has a Hold consensus rating as of Aug 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nevro (NVRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.